In a report released today, Derek Archila from Stifel Nicolaus maintained a Buy rating on Argenx Se (NASDAQ: ARGX), with a price target of $139. The company’s shares opened today at $76.64.
Archila wrote:
“Price .Financial Rating — Buy Target Price — $139.00 FY18E Revenue — €35.0 FY19E Revenue — €35.0 Price ( 10/25/18 ): $74.82 52-Week Range: $103 – $22 2,424.2 Shr.O/S-Diluted (mm): 32.4 $12.10 Dividend / Yield: $0.00 / 0.0% Price is intraday, October 25, 2018.”
According to TipRanks.com, Archila has 0 stars on 0-5 star ranking scale with an average return of -8.2% and a 28.6% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Rhythm Pharmaceuticals Inc, and Pacira Pharmaceuticals.
Argenx Se has an analyst consensus of Strong Buy, with a price target consensus of $138.71, implying an 81.0% upside from current levels. In a report issued on October 15, Evercore ISI also initiated coverage with a Buy rating on the stock with a $110 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $103 and a one-year low of $22.21. Currently, Argenx Se has an average volume of 240.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
argenx SE is a clinical-stage biotechnology company, which engages in the research and development of human monoclonal antibodies for the treatment of cancer and oncological, autoimmune, and inflammatory diseases. Its products include ARGX-113 for severe autoimmune diseases and ARGX-110 for T-cell lymphoma and acute myeloid leukemia.
